Robertson, John F. R. http://orcid.org/0000-0001-6212-3979
Di Leo, Angelo
Johnston, Stephen
Chia, Stephen
Bliss, Judith M.
Paridaens, Robert J.
Lichfield, Jasmine
Bradbury, Ian
Campbell, Christine
Article History
Received: 29 May 2020
Accepted: 8 January 2021
First Online: 12 February 2021
Competing interests
: J.F.R.R. has received consulting fees from, and has performed contracted research on behalf of, AstraZeneca, Bayer, Novartis and Oncimmune; has given expert testimony for AstraZeneca; and holds stock with Oncimmune. A.D.L. reports personal fees from AstraZeneca, Bayer, Celgene, Daichii-Sankyo, Eisai, Eli Lilly, Genentech, Genomic Health, Ipsen, Pierre Fabre, Roche and Seattle Genetics; and grants and personal fees from Novartis and Pfizer Inc. S.J. has received consultancy fees from, and has performed contacted research on behalf of, AstraZeneca, Eli Lilly, Novartis, Pfizer Inc and Puma Biotechnology; and has been a member of the speakers’ bureaus for AstraZeneca, Eisai, Novartis and Pfizer Inc. S.C. received consulting fees from AstraZeneca, Novartis, Pfizer Inc and Roche; and has performed contracted research on behalf of AstraZeneca, Bristol-Myers Squibb, Genetech, Hoffmann-La Roche, Novartis and Pfizer Inc. J.M.B. has received grant funding and non-financial support from AstraZeneca, Clovis Oncology, Janssen-Cilag, Merck, Pfizer Inc, Puma Biotechnology, and Merck Sharp and Dohme; and grant funding from Medivation. J.L. is an employee of Eisai; and a stockholder and a former employee of AstraZeneca. R.J.P., I.B. and C.C. have no conflicts of interest to declare.